Healthcare Industry News: diabetes
News Release - September 1, 2015
SI-BONE, Inc. Appoints Karen Licitra and Keith Valentine to its Board of DirectorsSAN JOSE, Calif., Sept. 1, 2015 -- (Healthcare Sales & Marketing Network) -- SI-BONE, Inc., a medical device company that pioneered the use of the iFuse Implant System®, a minimally invasive surgical (MIS) device indicated for fusion for certain disorders of the sacroiliac (SI) joint, announced that Karen Licitra and Keith Valentine have been appointed to its Board of Directors.
Ms. Licitra was recently Corporate Vice President at Johnson & Johnson where she led Worldwide Government Affairs & Policy. In this role, she was responsible for Johnson & Johnson's engagements with global government leaders at the multilateral, national and state levels. Her organization also led development of Johnson & Johnson public policy. Previously, Karen was Worldwide Chairman of the Global Medical Solutions Group within Johnson & Johnson's Medical Device and Diagnostics segment. In that role, she was responsible for establishing the strategy and vision for an $8 billion global portfolio of healthcare companies including Vision Care, diabetes Care, Ortho Clinical Diagnostics, and Advanced Sterilization Products, as well as the Sedation business unit. She was named to Fortune's 50 Most Powerful Women in Business list in 2012.
Mr. Valentine is currently President and Chief Executive Officer of SeaSpine Holdings Corporation, a medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. Prior to joining SeaSpine, Mr. Valentine served as President and Chief Operating Officer of NuVasive, Inc. from January 2007 to January 2015 and as President from December 2004 to January 2007, prior to which he served in various senior executive roles in Marketing, Development and Operations after joining NuVasive in 2001. Previously, Mr. Valentine held executive positions at ORATEC that was acquired by Smith & Nephew PLC, and spent eight years in various senior roles with Medtronic Sofamor Danek.
"We are extremely pleased and honored to have both Karen and Keith join our Board of Directors simultaneously. Individually, they have each built distinguished careers that span decades of impressive leadership and accomplishments, and both are highly respected in the medical device industry. We look forward to their guidance and contribution as SI-BONE moves into our next phase of growth," said Jeffrey Dunn, President and CEO of SI-BONE.
"I am thrilled to be joining an organization that so highly values clinical evidence and is focused on improving patients' lives," said Ms. Licitra. "I look forward to contributing to SI-BONE's ongoing success and commercial efforts."
"I am pleased to join SI-BONE's Board of Directors, and look forward to working with the Board and team to help execute on a solid strategy as the company continues to grow and build out its business," said Mr. Valentine.
About SI-BONE, Inc.
SI-BONE, Inc. (San Jose, California) is the leading sacroiliac joint medical device company dedicated to the development of tools and products for patients with low back issues related to certain SI joint disorders. The company has developed, and is manufacturing and marketing, minimally invasive products for patients with these disorders. SI-BONE, Inc. received original 510(k) clearance in November 2008 from the Food and Drug Administration (FDA) to market its iFuse Implant System. The CE mark for European commercialization was obtained in November 2010.
The iFuse Implant System is a minimally invasive surgical option that uses titanium implants coated with a porous, titanium plasma spray (TPS) that acts as an interference surface, designed to help decrease implant motion, provide immediate fixation and allow for biological fixation to support long term fusion. The iFuse Implant System is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. There are potential risks associated with the iFuse Implant System. It may not be appropriate for all patients and all patients may not benefit. For information about the risks, visit: www.si-bone.com/risks.
SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc. ©2015 SI-BONE, Inc. All Rights Reserved. 9200.090115
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.